There is a demand for safe and potent anti-obesity drugs, because currently available anti-obesity drugs, such asorlistat (gastrointestinal lipase inhibitor) and fibrates (PPARα agonists), cause undesirable side effects. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.